What is pjp in medical terms

Medical Definition and Classification

In medical terminology, PJP is an abbreviation for Pneumocystis Jirovecii Pneumonia. This is a serious opportunistic infection of the lungs caused by the fungus Pneumocystis jirovecii. The infection develops in individuals with severely compromised immune systems, most commonly those with untreated HIV infection (particularly when CD4 T-cell counts are below 200 cells/µL), organ transplant recipients receiving immunosuppressive therapy, or those on prolonged corticosteroid treatment. PJP is classified as an opportunistic infection because it typically only develops when immune defenses are severely weakened.

Pathophysiology and Disease Mechanism

The Pneumocystis jirovecii organism exists in the respiratory tract and environment but remains dormant or controlled in immunocompetent individuals. In immunocompromised hosts, the organism proliferates unchecked, causing progressive inflammation and infiltration of the alveolar spaces—the tiny air sacs where gas exchange occurs in the lungs. This leads to impaired oxygen diffusion into the bloodstream, resulting in hypoxemia (low blood oxygen levels). The infection gradually worsens, causing progressive dyspnea (shortness of breath), tachypnea (rapid breathing), and potentially acute respiratory failure if treatment is delayed or unavailable.

Clinical Presentation and Diagnostic Approach

Patients with PJP typically present with subacute onset of dyspnea, nonproductive cough, fever, and chest discomfort. The progression is usually gradual over weeks, distinguishing it from acute bacterial pneumonia. Diagnosis relies on clinical suspicion combined with imaging studies showing bilateral interstitial infiltrates and confirmation through identification of the organism in induced sputum, bronchoalveolar lavage specimens, or tissue samples. Elevated serum lactate dehydrogenase (LDH) is a typical laboratory finding that supports the diagnosis. PCR testing has become increasingly useful for rapid confirmation.

Treatment Protocols and Clinical Management

First-line medical treatment is trimethoprim-sulfamethoxazole (TMP-SMX), administered for 21 days. Alternative antimicrobial agents include pentamidine, atovaquone, dapsone with trimethoprim, or clindamycin with primaquine for patients with sulfonamide allergies or intolerance. Adjunctive corticosteroids (typically prednisone) are often used in moderate to severe cases to reduce lung inflammation and improve outcomes. Prophylaxis with TMP-SMX or alternative agents is recommended for all HIV patients with CD4 counts below 200 cells/µL and in other immunocompromised populations at significant risk.

Epidemiology and Current Clinical Significance

Before the advent of effective antiretroviral therapy (ART) in the mid-1990s, PJP was one of the most common AIDS-defining illnesses in developed countries, affecting a majority of untreated AIDS patients. In the post-ART era, PJP incidence has dramatically declined among HIV-positive patients in resource-rich settings with good treatment access. However, it remains an important opportunistic infection in areas with limited ART access, in patients with delayed HIV diagnosis, and in those with poor treatment adherence. PJP mortality has significantly improved with modern treatments compared to the pre-ART era.